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The angelicin analogue 4,6,4′-trimethylangelicin (TMA) was recently reported as a strong inhibitor of nuclear factor-κB (NF-κB)
activity and of the expression of the interleukin-8 (IL-8) gene in bronchial epithelial cells in which the inﬂammatory response
has been challenged with P. aeruginosa, the most common bacterium found in the airways of patients aﬀected by cystic ﬁbrosis
(CF). These ﬁndings encouraged us to analyze new synthetic analogues of TMA in order to evaluate their biological activities on
human bronchial epithelial CF IB3-1 cells and to ﬁnd more potent anti-NF-κB agents exhibiting only minor antiproliferative
eﬀects. Analogues able to inhibit NF-κB/DNA interaction at lower concentration than TMA were found and selected to
investigate their biological activity on IB3-1 cells induced with TNF-α. In this biological system, NF-κB-mediated IL-8 gene
expression was investigated. Some analogues showed similar activity to the lead compound TMA. Other analogues displayed
higher activities; in particular, the most interesting compounds showing relevant anti-inﬂammatory eﬀects were found to cause
56–83% reduction of IL-8 mRNA expression at low concentrations (1–10 μM), without changes in cell proliferation pattern,
demonstrating their potential interest for a possible development of anti-inﬂammatory therapy of cystic ﬁbrosis.
1. Introduction
Psoralens, also known as furocoumarins, are naturally
occurring or synthetic tricyclic aromatic compounds,
deriving from the condensation of a coumarin nucleus
with a furan ring [1, 2]. The furan moiety may be fused
in diﬀerent ways producing several isomers: linear isomers
(psoralens; Figure 1(a)) and angular isomers (angelicins,
Figure 1(b); allopsolarens, Figure 1(c)) [3]. The most
abundant linear furocoumarins are psoralen, xanthotoxin,
and bergapten; whereas the angular type ismostly represented
by angelicin [3].
Furocoumarins are found in natural plant extracts
belonging to angiosperm families, formerly used in popular
medicine: for example, angelicin is present in Angelica arch-
angelica (Apiaceae), allopsoralen in Mammea americana
(Guttiferae), and psoralens in Psoralea corylifolia (Legumi-
nosae) and Amni majus (Apiaceae) [4–6]. Bergapten is found
in Citrus bergamia (Rutaceae) [7].
At present, several psoralens are used also in conven-
tional medicine in the treatment of various skin diseases
(mainly vitiligo and psoriasis) [8], using PUVA therapy
(Psoralen plus UVA light) [9]. The natural angular angelicin
(ANG), used in folk medicine, and its synthetic derivative
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4,6,4′-trimethylangelicin (TMA) were described in recent
studies of our research group [10, 11]. TMA was found
to be potentially useful in the treatment of cystic ﬁbrosis
(CF), thanks to its anti-inﬂammatory activity and its
potentiating action on the CFTR membrane channel
whose dysfunction causes that disease. Moreover, TMA
resulted to be a new corrector, showing actually a third
pharmacological activity [12, 13].
Cystic ﬁbrosis, a genetic disease that primarily aﬀects the
lungs and digestive system, is the most common autosomal
recessive disease in Caucasians associated with early death
[14, 15]; it is a complex multisystem disease caused by defects
in a single gene that is CFTR (cystic ﬁbrosis transmembrane
conductance regulator), which encodes for a chloride channel
expressed in several epithelia [16]. Pulmonary inﬂammation
is responsible formost of themorbidity andmortality because
the most important clinical complication is focalized in the
airway tract of aﬀected patients [17, 18]. In the healthy lung,
CFTR is detectable on the apical membrane of ciliated cells
within the gland ducts and in the superﬁcial epithelium of
healthy individuals. In CF, the submucosal glands and distal
airways are obstructed by thick tenacious secretions, resulting
in a failure of normal mucociliary clearance and defective
airway defense mechanisms against inﬂammation and bacte-
rial infection. Therefore, inhibition of the proinﬂammatory
pathways in CF appears to be clinically relevant [19–21].
In this context, the contribution of nuclear factor-kappaB
(NF-κB) in chronic inﬂammatory and autoimmune diseases
is well known in CF. The activation of NF-κB triggers proin-
ﬂammatory cytokine production [22, 23]. Therefore, target-
ing NF-κB might be a very interesting strategy in CF, since
NF-κB has been ﬁrmly linked to the IL-8 (interleukin-8) gene
expression [24], which is a key chemokine activated in Pseu-
domonas aeruginosa induction of state of CF lung. Targeting
NF-κB has been reported using DNA-based drugs, such as
decoy oligonucleotides [24–27], as well as low molecular
weight molecules [28, 29]. However, NF-κB has also been
reported as an antiapoptotic factor related to cell growth,
suggesting that NF-κB inhibitors (as found for TMA) might
exhibit antiproliferative and/or cytotoxic eﬀects.
In order to improve the anti-inﬂammatory activity of
TMA and to reduce some related cytotoxic eﬀects, we
analyzed new thirty-eight TMA derivatives belonging to
diﬀerent chemical classes (series) and reported in Table 1,
in order to verify whether compounds are present displaying
eﬀects on NF-κB, inﬂammatory-related proteins without
major alteration of cell growth potential.
2. Materials and Methods
2.1. Synthesis and Characterization of TMA Analogues.
TMA (4,6,4′-trimethylangelicin) was synthesized at the
Department of Pharmaceutical Sciences of the University of
Padova [30], and it was dissolved in a mixture of methanol
(MeOH) and 3% of dimethyl sulfoxide (DMSO) to obtain
the 10mM stock solution, stored at −20°C in the dark. The
working solutions were then obtained using MeOH. TMA
analogues were partly synthesized as previously described
[31–40] and partly belong to the collection of the Organic
Synthesis Lab (Dept. of Pharmaceutical Sciences, University
of Padova). The stock solutions (100mM) of each compound
were prepared in DMSO and were diluted with MeOH
to obtain the desired working solutions (10mM-500μM),
immediately before the in vitro experiments and treatment
of cell cultures. No eﬀect of the maximum concentrations
employed on the vehicles on the test performed (cell growth,
gene expression) was observed.
2.2. EMSA (Electrophoretic Mobility Shift Assays). Elec-
trophoretic mobility shift assays were performed using
double-stranded 32P-labeled oligonucleotides as target DNA.
Binding reactions were set up as previously described
[19] in binding buﬀer (10% glycerol, 0.05% NP-40,
10mM Tris-HCl pH 7.5, 50mM NaCl, 0.5mM DTT,
and 10mM MgCl2), in the presence of 0.1μl/20μl of
NF-κB p50 (50 gsu) (Promega, Madison, WI, USA) and
0.25 ng of labeled oligonucleotide, in a total volume of
20μl. After 30min binding at room temperature, samples
were electrophoresed at constant voltage (200V for 30min)
through a low ionic strength (0.25TBE buﬀer) (1TBE/
40.089M Tris-borate, 0.002M EDTA) on 6% polyacrylamide
gels until the tracking dye (bromophenol blue) reached the
bottom of a 16 cm slab. Gels were dried and exposed for
autoradiography with intensifying screens at 80°C. In these
experiments, DNA/protein complexes migrate through the
gel with slower eﬃciency. In studies on the inhibitors of
protein/DNA interactions, addition of the reagents was as
follows: (i) nuclear factors, (ii) active principles, (iii) binding
buﬀer, and (iv) labeled oligonucleotides mimicking the bind-
ing sites for TF to be modulated. The nucleotide sequence of
double-stranded target DNA utilized in these experiments
was 5′-CGC TGG GGA CTT TCC ACG G-3′ (sense strand,
NF-κB). The synthetic oligonucleotides utilized in this study
were purchased from Sigma Genosys (Sigma Genosys,
Cambs, UK). To calculate the eﬀective concentrations, three
diﬀerent autoradiograms obtained from diﬀerent time
exposures were scanned and compared to control EMSA
performed without addition of angelicin analogues (two
independent experiments were performed).
2.3. Cell Cultures. IB3-1 cells, derived from a CF patient with
a ΔF508/W1282X mutant genotype and immortalized with
adeno12/SV40, were grown in LHC-8 supplemented with
5% FBS in the absence of gentamycin, at 37°C/5% CO2 [12].
2.4. Cell Proliferation Assays. Monolayers of 60% conﬂuent
IB3-1 cells were seeded in 24- or 12-well plates in LHC-8
medium in the presence of 5% FBS. After 24h, TMA deriva-
tives were added at serial dilutions and incubated for further
2-3 days. The eﬀects of compounds (TMA derivatives) on the
cell proliferation were analyzed as elsewhere described. A
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Figure 1: Chemical skeleton of linear and angular furocoumarins.
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Table 1: Chemical structure of lead compound 4,6,4′-trimethylangelicin (TMA) and of TMA analogues.
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Table 1: Continued.
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ﬁrst analysis was performed with serial dilutions to obtain
50μM, 200μM, and 800μM solutions. In order to determine
IC50 values, the following concentrations were used 12.5,
25, 50, 100, 200, and 800μM. In order to prepare the cells
for counting, they were washed with PBS 1X and detached
with trypsin/EDTA. Cells were suspended in physiological
solution and counted with a Z2 Coulter Counter (Coulter
Electronics, Hialeah, FL, USA). The cell number/ml was
determined as IC50 after 2 days of culture, when untreated
cells are in log phase of cell growth.
2.5. Quantiﬁcation of IL-8 mRNA Content. Monolayers of
60% conﬂuent IB3-1 cells were seeded in 6- or 12-well plates
in LHC-8 medium in the presence of 5% FBS. After 24h,
pure derivatives were added, 5 h before stimulation with
TNF-α 80 ng/ml (ORF Genetics, Kopavogur, Iceland), and
incubated for a further 24h. Total RNA was extracted using
TRIzol Reagent (Sigma-Aldrich, St. Louis, MO) following
the manufacturer’s instructions. Reverse transcription (RT)
was performed using Reverse Transcription System kit
(Promega, Madison, WI): 1μg of total RNA was reverse
transcribed in the presence of 5mM MgCl2, 1X reverse
transcription buﬀer (10mM Tris-HCl, 50mM KCl, and
0.1% Triton X-100), 1mM each dNTPs, 20U recombinant
Rnasin Ribonuclease Inhibitor, 15U AMV Reverse Tran-
scriptase, and 0.5μg oligo(dT)15 primers in a total volume
of 20μl for 10min at 70°C and 60min at 42°C. The resulting
cDNA was quantiﬁed by relative quantitative real-time PCR
(real-time qPCR). For real-time qPCR, 1μl of cDNA was
used for each SYBR Green reaction to quantify the relative
expression of IL-8. Each 25μl of total reaction volume con-
tained 1μl of cDNA, 10 pmol of primers, 1 iQTM SYBR
Green Supermix (Bio-Rad Laboratories Inc., Hercules, CA).
Real-time PCRs were performed for a total of 40 cycles
(denaturation, 95°C for 10 s; annealing, 68°C for 30 s for
IL-8, 65°C for 30 s for IL-6; elongation, 72°C for 60 s)
using an iCycler IQ5 (Bio-Rad Laboratories Inc., Hercules,
CA). Primer sequences were as follows: IL-8 forward:
5′-GTG CAG TTT TGC CAA GGA GT-3′ and IL-8
reverse: 5′-TTA TGA ATT CTC AGC CCT CTT CAA
AAA CTT CTC-3′. The relative proportions of each ampli-
ﬁed template were determined utilizing the threshold cycle
(CT) value for each performed PCR. The DDCt method
was used to compare gene expression data. Each sample
was quantiﬁed in duplicate. Changes in mRNA expression
level were calculated following normalization with the
GAPDH calibrator gene (housekeeping gene) and expressed
as fold change over untreated samples [24]. Duplicates of
negative controls (no template cDNA) were also run with
every experimental plate to assess speciﬁcity and indicate
potential contamination.
2.6. Bioplex Analysis. Cytokines, released from cells into tis-
sue culture supernatants, were measured by Bioplex cytokine
assay (Bio-Rad Laboratories Inc., Hercules, CA) as suggested
by the manufacturer (Luminex technology) [41]. The Bioplex
cytokine assay is designed for the multiplexed quantitative
measurement of multiple cytokines in a single well using as
little as 50μl of sample. In our experiments, the premixed
multiplex beads (27-plex) of the Bioplex human cytokines
were used. 50μl of cytokine standards or samples (superna-
tants recovered from treated cells and diluted to 2μg/μl) were
incubated with 50μl of anticytokine conjugated beads in
96-well ﬁlter plates for 30min at room temperature with
shaking. Plates were washed by vacuum ﬁltration three
times with 100μl of Bioplex wash buﬀer, 25μl of diluted
detection antibody were added, and plates were incubated
for 30min at room temperature with shaking. After three
ﬁlter washes, 50μl of streptavidin-phycoerythrin were
added, and the plates were incubated for 10min at room
temperature with shaking. Finally, plates were washed by
vacuum ﬁltration three times, beads were suspended in Bio-
plex assay buﬀer, and samples were analyzed on a Bio-Rad
96-well plate reader using the Bioplex Suspension Array
System and Bioplex Manager software (Bio-Rad Laboratories
Inc., Hercules, CA).
Table 1: Continued.
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3. Results
3.1. Eﬀects of TMA Derivatives on the In Vitro Proliferation of
Cystic Fibrosis IB3-1 Cells. In order to obtain preliminary
information on the biological properties of TMA derivatives,
their eﬀects on cell growth were examined on IB3-1 cell line,
excellent biological model to study new potential anti-
inﬂammatory molecules. The use of this cell line to study
the expression of proinﬂammatory molecules under a variety
of stimuli is well established. Monolayers of 60% conﬂuent
IB3-1 cells were seeded in 12-well plate in LHC-8 medium
with 5% FBS. After 24 h, compounds were added at diﬀerent
concentrations and the cell number/ml was determined after
further 48 h of culture. All the obtained IC50 values are
reported in Table 2.
Several TMA analogues displayed very low antiprolifera-
tive eﬀects (>800μM), such as compounds 1–4, 7, 9, 12–16,
18, 27–34, 36, and 37. This lack of antiproliferative activity of
these angelicin analogues was conﬁrmed in further experi-
ments, fully sustaining the conclusion that these analogues
do not cause 50% inhibition of cell growth even when added
at high concentration, being therefore of interest in the
identiﬁcation of possible inhibitors of inﬂammation-related
genes without major toxic eﬀects. TMA exhibited an IC50
value of 185± 30μM (data not shown).
3.2. In Vitro Inhibition of NF-κB/DNA Interactions. The
eﬀects of TMA derivatives on NF-κB- (nuclear factor-
kappaB-) mediated induction of proinﬂammatory genes
was veriﬁed ﬁrst in vitro by electrophoretic mobility shift
assay (EMSA) with the aim to verify and quantify the possible
inhibition of NF-κB/DNA interactions. This assay was per-
formed using puriﬁed NF-κB p50 and 32P-labeled target NF-
κB double-stranded oligonucleotide mimicking the NF-κB
consensus sequence present within the IL-8 gene promoter.
We ﬁrst conﬁrmed that TMA is able to suppress NF-κB/
DNA interactions when used at 100μM concentration
(Figure 2); to verify whether new analogues were more active
than the TMA lead compound, we performed an EMSA-
based screening considering the TMA lowest active concen-
tration to be higher than 20μM(Figure 2 anddata not shown).
Preliminary data demonstrated that, when used at
100μM concentration, several derivatives fully suppress the
interactions between NF-κB p50 and the target DNA, while
other molecules (compounds 2, 3, 6, 7, 11, 14, 15, 17, 22,
and 24) were not analyzed because the relative EMSA exper-
iments demonstrated low activity (MIC> 100μM) (data not
shown). According to these ﬁrst results, further analyses were
performed using diﬀerent dilutions of the selected active
compounds, exhibiting MIC values ranging from 12.5μM
to 100μM, as represented in Figures 3 and 4 and summarized
in Table 3, reporting their MIC values.
Among the “4,6,4′ series” (compounds 1, 2, and 3),
the most interesting molecule was compound 1, showing
MIC< 12.5μM, while 4 and 5 derivatives, belonging to the
“4,6 series” were active at 75μM and 25μM, respectively.
The “6,4′ series,” including 8, 9, and 10 analogues, dis-
played excellent inhibitory activities (35μM, 12.5μM, and
<12.5μM MIC, resp.).
In the same ﬁgure, we may also observe high activity of
12 and 13 derivatives (“4,4′ series”) showing low MIC value
(12.5μM), while among the “thio-series” (14, 15, and 16),
only 16 demonstrated a 50μM MIC value. All furoquinoli-
none analogues, belonging to the “FQ series” (17, 18, and
19), were considered inactive when compared with TMA
(MIC> 100μM).
Among derivatives belonging to “other angelicins” group,
compounds 23, 25, and 26 were able to inhibit the NF-κB/
DNA interaction showing MIC values of 25–50μM.
Table 2: IC50 values calculated after 48 h from treatment of IB3-1
cells with serial dilutions of TMA derivatives.
Derivative IC50 (48 h)
1 >800 μM
2 >800 μM
3 >800 μM
4 >800 μM
5 485.89μM
6 454.35μM
7 >800 μM
8 397.87μM
9 >800 μM
10 <50 μM
11 181.78μM
12 >800 μM
13 >800 μM
14 >800 μM
15 >800 μM
16 >800 μM
17 193.07μM
18 >800 μM
19 131.12μM
20 154.43μM
21 677.87μM
22 179.92μM
23 451.66μM
24 196.53μM
25 551.23μM
26 90.84μM
27 >800 μM
28 >800 μM
29 >800 μM
30 >800 μM
31 >800 μM
32 >800 μM
33 >800 μM
34 >800 μM
35 137.31μM
36 >800 μM
37 >800 μM
38 505.81μM
6 Mediators of Inﬂammation
All the derivatives starting from 27 to 38 showed
interesting MIC values in EMSA (Figure 4). Indeed, we
observed a MIC value< 12.5μM for the chromone deriv-
ative 27. The 3,4 analogue 28 inhibits the NF-κB/DNA
interaction at 15μM.
Among “difuro series,” we observed a MIC value<
12.5μM when 29 is added to binding reaction, and we
observed an MIC value of 15μM for derivative 30.
Triazole analogue 31 demonstrated its activity at 25μM.
Among “allo series,” two TMA isosters, 32 and 33,
showed MIC values of 12.5μM and 15μM, respectively.
Among “pyran series,” compound 36 demonstrated the
most interesting inhibitory eﬀect showing 15μMMIC value;
derivative 35 was able to interfere with the NF-κB/DNA
interaction at 35μM MIC. Finally, two coumarin com-
pounds, 37 and 38, both exhibited active at 25μM MIC.
In conclusion, several TMA derivatives were found to be
more active than the reference compound TMA, such as 1, 5,
10, 12, 23, 27–29, 31, 32, 34, and 36–38.
3.3. Inhibition of IL-8 mRNA Accumulation in TNF-α-
Treated IB3-1 Cystic Fibrosis Cells. With the aim to study
the eﬀective anti-inﬂammatory properties of these new
psoralen derivatives, we decided to further characterize the
TMA derivatives for their potential activities on the expres-
sion of IL-8 gene, known to be involved in the lung inﬂam-
matory process in CF. It is ﬁrmly established that IL-8 gene
expression is regulated at least in part by the NF-κB tran-
scription factor [24–26]; therefore, since molecules inhibiting
NF-κB/DNA interactions might exhibit inhibitory activities
on NF-κB-regulated genes [27], we were interested in
determining the activity of TMA analogues on IL-8 gene
expression. More speciﬁcally, we were ﬁrst interested in iden-
tifying compounds with low antiproliferative activity, but
eﬀective in downmodulating inﬂammatory gene expression
without achieving a full suppression of these genes. We
therefore employed IB3-1 cystic ﬁbrosis cells, incubated for
5 h with two concentrations (1μM and 10μM) of selected
compounds, and then treated with TNF-α (100μg/ml). In
the IB3-1 cystic ﬁbrosis cellular model, NF-κB-dependent
genes, including the gene encoding for the proinﬂammatory
protein IL-8, generally are activated following infection with
P. aeruginosa or treatment with TNF-α or IL-1β [26, 28, 31].
This feature is very important in the pathophysiology of CF,
since several clinical complications are caused by exacerba-
tion of this inﬂammatory response. After 1 day of incubation,
cellular RNA was isolated for RT-qPCR analysis. All the
TMA analogues found to be active in inhibiting NF-κB/
DNA interactions were analyzed for their eﬀects on inhibi-
tion of TNF-α-induced accumulation of IL-8 mRNA.
The results of RT-qPCR analyses obtained are summa-
rized in Table 3. Our results demonstrated that treatment
of IB3-1 cells with TNF-α induces a fast and sharp IL-8 gene
overexpression. This eﬀect is clearly inhibited by the presence
of some TMA derivatives, the most active being 1, 8, 26, 32,
33, 34, 36, and 38.
3.4. Bioplex Analysis. In order to verify the eﬀects on the
secretion of IL-8 by IB3-1 cells, Luminex technology was
employed to detect and quantify proteins secreted into the
medium. This proof-of-principle was conducted on com-
pound 1 since using high concentrations of this compound,
no antiproliferative activity was observed (IC50> 800μM),
despite the fact that this compound was one of the most
active in inhibiting NF-κB/DNA interactions (see Figure 3).
The found results were in full agreement with those obtained
studying IL-8 mRNA accumulation, showing that the inhibi-
tion of IL-8 is higher than that induced by TMA. This is
shown in Figure 5, which supports the decrease of IL-8
expression during treatment with derivative 1 (1μM), show-
ing about 50% reduction of IL-8 secretion when compared to
untreated, TNF-α-stimulated cells. This eﬀect was higher
than 1μM TMA and similar to that found with 10μM
TMA. The higher eﬃciency of compound 1 with respect to
TMA was reproducibly observed in three independent exper-
iments. As far as the other cytokines, chemokines, and
growth factors that can be analyzed with the Bioplex
approach, only minor (less than 10% variation) eﬀects
were found for all the secreted proteins analyzed with
the exception of the TNF-α-inducible IP-10, which was
further increased (more than twofold in three independent
experiments). Altogether, these data suggest that com-
pound 1 is a very interesting inhibitor of proinﬂammatory
cytokine’s activities.
4. Discussion
Psoralens are well-known furocoumarins belonging to the
class of photosensitizers used for their activity in the treat-
ment of various chronic inﬂammatory skin diseases, and they
are characterized by a diﬀerently substituted tricyclic aro-
matic skeleton, derived from condensation of a coumarin
nucleus with a furan ring. Among psoralen-related com-
pounds, the angular angelicin- (ANG-) like isomers are both
synthetic and natural compounds that we demonstrated
exhibiting interesting pharmacological activities compared
with linear psoralens [11].
Recently, we established that 4,6,4′-trimethylangelicin
(TMA) is a strong inhibitor of the expression of the IL-8 gene
in bronchial epithelial cells in which the inﬂammatory
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Figure 2: Eﬀects of TMA on the molecular interactions between
NF-κB p50 and a 32P-labeled target NF-κB double-stranded
oligonucleotide. TMA was ﬁrst incubated with NF-κB, and then the
32P-labeled target NF-κB oligonucleotide was added. NF-κB/DNA
complexes were analyzed by polyacrylamide gel electrophoresis.
Arrow indicates NF-κB/DNA complexes; asterisk indicates the free
32P-labeled target NF-κB probe.
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response has been challenged with P. aeruginosa [12], the
most common bacterium found in the airways of patients
aﬀected by cystic ﬁbrosis (CF). These ﬁndings suggested us
to continue our research analyzing 38 new analogues of
TMA in order to evaluate their biological activities on
human bronchial epithelial cells IB3-1, derived from a
CF patient with a ΔF-508/W1282X mutant genotype. This
cellular system is very attractive, since it is well known
that the hallmark in CF airway pathology is a characteris-
tic elevated concentration of proinﬂammatory cytokines
and chemokines, the most important of which seems to
be IL-8.
In the ﬁeld of research about CF, the study of novel and
innovative drugs for the treatment of this pathology is con-
stantly evolving in order to ameliorate the clinical conditions
of patients. In the conventional treatment of CF, the com-
monly utilized drugs are nonsteroidal anti-inﬂammatory
drugs (NSAIDs) and steroid derivatives that possess, in
addition to great beneﬁts, many known side eﬀects. The
search for modern therapies to counteract the inﬂammation
in CF patients is aimed at ﬁnding new potential anti-
inﬂammatory drugs with alternative mechanisms of action
that may replace the use of typical drugs.
In inﬂammatory processes that involve patients with CF,
NF-κB transcription factor plays a crucial role. Indeed, the
expression of many genes encoding for cytokines, chemo-
kines, adhesion molecules, and other proteins involved in
inﬂammation is regulated by NF-κB. The NF-κB dimers, as
the predominant p50/p65 heterodimer, following a cascade
of intracellular biochemical events activated by extracellular
stimuli including cytokines as TNF-alpha (TNF-α), are left
free to move into the nucleus, where they activate speciﬁc
proinﬂammatory genes. For this reason, it is extremely inter-
esting to ﬁnd new potential anti-inﬂammatory drugs, which
inhibit the action of NF-κB and the subsequent production
of cytokines (particularly IL-8).
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Figure 3: Representative results depicting the eﬀects of TMA analogues (1–26) at 12.5–100μM concentrations, compared to TMA in EMSA
experiments on the molecular interactions between NF-κB p50 and 32P-labeled target NF-κB double-stranded oligonucleotide.
Compounds 2, 3, 6, 7, 11, 14, 15, 17–22, and 24 were not analyzed because the relative EMSA experiments demonstrated low activity
(MIC> 100 μM). Arrow indicates NF-κB/DNA complexes; asterisk indicates the free 32P-labeled target NF-κB probe.
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Because our previous studies demonstrated that TMA
inhibits NF-κB/DNA interactions in vitro in EMSA exper-
iments at 100μM concentration [12], band shift analyses
were performed to ﬁnd new derivatives able to inhibit
the interaction between puriﬁed p50 subunit of NF-κB
and DNA-speciﬁc target mimicking IL-8 promoter. Con-
sidering these preliminary results, new TMA derivatives
able to inhibit NF-κB/DNA interaction at lower concentra-
tion than lead compound TMA were selected to investigate
their biological activity on IB3-1 cells induced with TNF-α.
In this system, NF-κB-dependent genes, including those
encoding for the proinﬂammatory protein IL-8, were investi-
gated. TNF-α-induced expression of IL-8 was evaluated by
quantitative reverse transcription and polymerase chain
reaction (RT-qPCR) in IB3-1 cells incubated with 1μM and
10μM of active compounds. All the obtained results are
summarized in Table 3.
The most interesting compounds showing relevant anti-
inﬂammatory eﬀects are compounds 1, 32, 33, 34, and 36
derivatives. As expected by EMSA results, these proralens
were able to reduce IL-8 mRNA expression of 57% (1μM),
73% (1μM), 66% (1μM), 68% (1μM), and 77% (1μM),
respectively, without antiproliferative eﬀects at the used
concentrations (IC50> 800mM). Biological activities of all
the analyzed TMA derivatives were observed at low concen-
trations (1–10μM), without changes in cell proliferation.
Other TMA analogues (8, 26, 33, and 38) showed high
Table 3: Results of RT-qPCR analysis reporting the % inhibition of
IL-8 mRNA in TNF-α-induced IB3-1 cells cultured with 1 μM and
10 μM concentrations of TMA derivatives.
Derivative
1 μM
(% inhibition)
10 μM
(% inhibition)
Inhibition of
NF-κB/DNA
complex (MIC) μM
1 57 56 <12.5 (∗)
5 33 31 12.5–25
8 51 52 25–50
12 0 na 12.5
16 18 21 25–50
23 3 11 2–505
25 na na 50–100
26 55 83 50–100
27 16 na <12.5 (∗)
28 21 36 12.5–25
29 na 12 <12.5 (∗)
30 10 na 12.5–25
31 na na 12.5
32 73 52 <12.5 (∗)
33 68 67 12.5–25
34 66 47 <12.5 (∗)
35 56 37 25–50
36 77 74 12.5–25
37 na na 12.5–25
38 36 81 25
na: not active at the used concentrations; MIC: minimal inhibitory
concentration. ∗In the EMSA experiments, 12.5 μM was the minor
concentration used.
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Figure 4: Representative results depicting the eﬀects of TMA
analogues (27–38) at 12.5–100μM concentrations, compared to
TMA in EMSA experiments on the molecular interactions
between NF-κB p50 and 32P-labeled target NF-κB double-stranded
oligonucleotide. Arrow indicates NF-κB/DNA complexes; asterisk
indicates the free 32P-labeled target NF-κB probe.
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Figure 5: Bioplex analysis of IL-8 release (pg/ml) in IB3-1 cells
induced with TNF-α in the absence and in the presence of
compound 1 (1μM); the eﬀects of 1μM and 10 μM TMA were
included for comparison (n = 3). IB3-1 cells were treated with
compound 1 for 5 hours and then stimulated with TNF-α for
further 24 hours. The supernatants were analyzed using a Bioplex
cytokine assay.
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inhibitory eﬀects (52–83%) on IL-8 expression in IB3-1
cell model, demonstrating their potential power in a possi-
ble anti-inﬂammatory therapy, together with 26, 38, 36,
and 32.
Some analogues, ﬁnally, including 2, 5, 7, and 28, showed
similar activity (33–38% of inhibition of IL-8 expression) to
the lead compound TMA, even though they were considered
not promising in EMSA assay.
The biological data allow to determine a very preliminary
SAR (structure-activity relationship). Almost all the active
compounds possess a tricyclic backbone with furocoumarin
structures. The heteroatoms in the policyclic skeleton must
be oxygen atoms, since all isosteric substitutions led to poorly
active or inactive compounds (“thio series” 14–18, “FQ
series” 17–19, and “triazole series” 31).
The steric hindrance of the substituent in the furo-
coumarin skeleton appears detrimental for the activity,
since almost all the active compounds are methyl deriva-
tives. Monohydroxymethyl derivatives ormonoaminomethyl
compounds are still active (8, 26, and 38), but more hindered
compounds are inactive.
The furan ring can be condensed at the 5,6 positions of
the central benzene ring (“allo series” 32–34) as well as at
the 7,8 positions (1, 5, 8, 26, and 28), without impairing the
activity, but not at both the positions at the same time
(“difuro series” 29-30). The furan ring can be replaced by a
pyran one maintaining a good inhibition of IL-8 expression
(“pyran series” 35-36). Moreover, the furan ring must be
fully aromatic, since the hydrogenated derivatives are inac-
tive (“dihydro series” 20–22).
The coumarin moiety must be in the α-pyron conforma-
tion since other structural disposition (γ-pyron) aﬀords
inactive product (“chromone series” 27).
Finally, the tricyclic derivatives appear to be the more
promising ones: the bicyclic derivatives are active only if a
substituent mimicking the furan shape is present at the 8
positions (“coumarin series” 38).
5. Conclusions
Our data conclusively allowed the identiﬁcation of novel
TMA analogues exhibiting improved inhibitory activity
on NF-κB/DNA interactions, IL-8 gene expression with
only minor eﬀects on cell growth. Although epithelial cells
lying the surface of the airway tract are considered good
sensors of the activity of promising anti-inﬂammatory
agents, the eﬀect of the most interesting TMA deriva-
tives should be in the future extended also to the whole
lung tissues of mice infected in vivo, in order to verify
the possibility of multiple anti-inﬂammatory eﬀects on
diﬀerent cells orchestrating the innate immune response in
the lung.
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